Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Pomalidomide + Dex + G-CSF in RRMM
NCT01946152Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2014
- Primary completion
- Mar 2020
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase II Dose at 28 days and 1 more. Started Mar 2014; status: terminated.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01946152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946152.